Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Genomic Instability in Alzheimer’s Disease and Related Disorders: a Single-Cell Approach

INSTALZ

Increasing evidence suggests that the genetic information in our bodies can vary from cell to cell. Such variation has also been found in the brain, although its consequences for brain function or disease remain largely unknown. In this project, we will study the role of genomic instability in Alzheimer's disease and related tauopathies. The...

Funding Programme
Start Date
End Date
Total Funding
€ 1 837 608
European Countries Involved

High-Throughput, High-Content Screening of human neuroectodermal organoids for innovative drug discovery in neurodegenerative diseases

3DMiniBrain

The goal of the 3D MiniBrain project is to establish and standardize the use of miniaturized human brain-like structures as a relevant three-dimensional (3D) testbed to decipher the roles of the main genetic risk factors for Alzheimer's disease and Parkinson's disease, according to original hypotheses obtained from our genetic studies. Minibrains...

Funding Programme
Start Date
End Date
Total Funding
€ 1 071 595
European Countries Involved

Identification of personalized inflammatory profiles of aging and senescence which are modified specifically by risk factors of dementia modulating the predementia speed of symptomatic progression.

PREADAPT

Age represents by far the largest risk factor for dementia, including Alzheimer’s disease (AD) dementia. However, not every person will develop dementia during aging, indicating that age-related processes may not inescapably lead to dementia. The elucidation of the fundamental processes occurring in aging will likely offer new options to prevent or...

Funding Programme
Start Date
End Date
Total Funding
€ 2 400 000
European Countries Involved

Identifying and treating SORL1-associated Alzheimer’s disease

SORLA-FIX

The majority of the risk to develop Alzheimer's disease is influenced by genetic factors. We previously found that carrying a genetic mutation in the SORL1 gene can lead to a greatly increased chance of developing Alzheimer's Disease. SORL1 is involved in the production and processing of Alzheimer proteins that accumulate in the brain. e have...

Funding Programme
Start Date
End Date
European Countries Involved

Innate Immune Activation in Neurodegenerative Disease

InCure

The mammalian central nervous system is an intricate and fragile structure which on one hand is open to change in order to store information, but at the same time is vulnerable to damage from injury, pathogen invasion or neurodegenerative diseases (NDs). Microglia, representing the brain`s innate immune system, execute a number of physiological...

Funding Programme
Start Date
End Date
Total Funding
€ 2 058 863
European Countries Involved

Loss of neurotrophic factors in neurodegenerative Dementias: Back to the crossroads of proteins

LODE

Neurodegenerative dementias are characterised by a continuous loss of neurons that are not replaced. Why neurons die in disease-affected brain regions is still a matter of discussion. This project explores a key common pathological mechanism across the three major neurodegenerative diseases leading to dementia: Alzheimer’s disease, Frontotemporal...

Funding Programme
Start Date
End Date
Total Funding
€ 1 020 000
European Countries Involved

Multimodal preventive trials for Alzheimer’s Disease: towards multinational strategies

MIND-AD

The anticipated pandemic increase in the number of Alzheimer disease (AD) and dementia cases carries serious implications for society. The goal of the MIND-AD project is to identify effective prevention strategies for AD/dementia tailored to different at-risk groups. The project is based on experiences and data from five ongoing European...

Funding Programme
Start Date
End Date
Total Funding
€ 0
European Countries Involved

Music Interventions for Dementia and Depression in ELderly care (MIDDEL): International cluster-randomised trial

MIDDEL

Many older adults living in residential care homes suffer from dementia and depression. MIDDEL aims to determine if music interventions can help. Specifically, this trial will provide robust and generalisable results concerning the comparative effects of group music therapy (GMT), recreational choir singing (RCS), their combination, or standard...

Funding Programme
Start Date
End Date
Total Funding
€ 2 600 000
European Countries Involved

Pathway complexities of protein misfolding in neurodegenerative diseases: a novel approach to risk evaluation and model development

REfrAME

Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementias and prion diseases affect ~50 million people worldwide. Alzheimer’s disease, the most prevalent form, affects ~6% of the population over 65 years of age and is one of the leading causes of death in the elderly. All these diseases have...

Funding Programme
Start Date
End Date
European Countries Involved

Personalised medicine approach for novel microglia-associated genetic variants in Alzheimer’s disease

PMG-AD

The role of inflammation and innate immune system in Alzheimer’s disease (AD) has been recently emphasized as GWAS and WES studies as well as functional studies have identified several AD-associated genes, including TREM2, ABI3, and PLCG2 that are expressed selectively or preferentially in microglia in the brain. These genetic and functional...

Funding Programme
Start Date
End Date
Total Funding
€ 1 400 000
European Countries Involved

PRE-CLINICAL GENOTYPE-PHENOTYPE PREDICTORS OF ALZHEIMER’S DISEASE AND OTHER DEMENTIA

APGeM

Alzheimer’s disease, Lewy-body dementias (including Parkinson’s disease) and other neurodegenerative dementias are major causes of disease, reduced patient- and caregiver quality of life, and increasing societal health costs. All have lengthy (decades) pre-dementia- and pre-clinical stages, but patients will have suffered irreversible brain damage...

Funding Programme
Start Date
End Date
Total Funding
€ 1 730 000
European Countries Involved

Precision Medicine Interventions in Alzheimer’s Disease

PMI-AD

Alzheimer’s disease (AD) is characterized by brain nerve cell death and dementia, but before dementia, leading up to these final and irreversible end-points we first see loss of synapses, which are the contacts between nerve cells allowing us to think, learn and function as independent beings. Coincident with early synaptic loss we also see...

Funding Programme
Start Date
End Date
Total Funding
€ 2 000 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).